Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme
Filed with HKEX · Stock code 6855 · · 2 pages · English
VOLUNTARY ANNOUNCEMENT PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME This announcement is made by Ascentage Pharma Group International (the “Company”) on a voluntary basis. Reference is made to the announcements of the Company dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October 27, 2022, October 28, 2022, October 31, 2022, Ma
Ascentage Pharma Group International on 6ix
Earlier from Ascentage Pharma Group International
- Interim report 2026
- Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
- CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
- Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
- Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Later from Ascentage Pharma Group International
- Voluntary announcement - acquisition of shares by the chairman and executive director
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - Ascentage Pharma's lisaftoclax granted breakthrough therapy designation in china for treatment-naive cll/sll
Follow Ascentage Pharma Group International into a list and get an email when it puts out news.
Follow Ascentage Pharma Group International